NEW YORK (GenomeWeb News) – Precision Biosciences said today that the US Patent and Trademark Office has granted the firm's request to reexamine a pair of US patents that Cellectis has asserted against Precision in ongoing patent-infringement litigation.

The patents, US Nos. 6,610,545 and 7,309,605, deal with DNA vectors that can be used in gene mapping and site-directed gene insertion. Cellectis has a license to the patents, which are owned by the Institut Pasteur and Universite Pierre et Marie Curie.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.